UK Medicines Information
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer – guidance (TA528)
Information type:
Guidance
Source:
National Institute for Health and Care Excellence
Specialities:
Cancers | Obstetrics and gynaecology
Summary
Niraparib is recommended, for use within the Cancer Drugs Fund, for relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum chemotherapy, with set restrictions.
UKMi comment
The restrictions are:
Patient has a germline BRCA mutation and has had 2 courses of platinum-based chemotherapy or
Patient does not have a germline BRCA mutation and has had 2 or more courses of platinum-based chemotherapy
Related links: